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ABSTRACT
Background and aim Severe adverse events (AEs)
compromise the outcome of direct antiviral agent-based
treatment in patients with advanced liver ﬁbrosis due to
HCV infection. HEP3002 is an ongoing multinational
programme to evaluate safety and efﬁcacy of telaprevir
(TVR) plus pegylated-interferon-α (PEG-IFNα) and
ribavirin (RBV) in patients with advanced liver ﬁbrosis
caused by HCV genotype 1 (HCV-1).
Methods 1782 patients with HCV-1 and bridging
ﬁbrosis or compensated cirrhosis were prospectively
recruited from 16 countries worldwide, and treated with
12 weeks of TVR plus PEG-IFN/RBV, followed by 12 or
36 weeks of PEG-IFN and RBV (PR) alone dependent on
virological response to treatment and previous response
type.
Results 1587 patients completed 12 weeks of triple
therapy and 4 weeks of PR tail (53% cirrhosis, 22%
HCV-1a). By week 12, HCV RNA was undetectable in
85% of naives, 88% of relapsers, 80% of partial
responders and 72% of null responders. Overall, 931
patients (59%) developed grade 1–4 anaemia (grade 3/
4 in 31%), 630 (40%) dose reduced RBV, 332 (21%)
received erythropoietin and 157 (10%) were transfused.
Age and female gender were the strongest predictors of
anaemia. 64 patients (4%) developed a grade 3/4 rash.
Discontinuation of TVR due to AEs was necessary in 193
patients (12%). Seven patients died (0.4%, six had
cirrhosis).
Conclusions In compensated patients with advanced
ﬁbrosis due to HCV-1, triple therapy with TVR led to
satisfactory rates of safety, tolerability and on-treatment
virological response with adequate managements of AEs.
INTRODUCTION
Chronic infection with HCV is a leading cause of
liver-related morbidity and mortality worldwide,
for which an effective antiviral treatment with
pegylated-interferon (PEG-IFN) and ribavirin (PR)
has been available since early 2000.1 2 The treat-
ment outcome for difﬁcult to cure patients, such as
those chronically infected with HCV genotype 1
(HCV-1), has remarkably improved following the
addition of the oral HCV protease inhibitors (PI)
boceprevir (BOC) or telaprevir (TVR) to PR
therapy.3–5 While eradication of HCV by PI+PR
therapy is expected to greatly extend treatment
success rates, resulting in a reduced risk of liver-
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Signiﬁcance of this study
What is already known on this subject?
▸ The treatment outcome for patients with
chronic hepatitis C due to genotype 1 of HCV
has remarkably improved following the addition
of the oral HCV protease inhibitors boceprevir
(BOC) or telaprevir (TVR) to pegylated
interferon+ribavirin (RBV) (PR) therapy.
▸ However, advanced hepatic ﬁbrosis may limit
both the access as well as the response rates of
patients to triple therapy with signiﬁcant issues
of tolerability and safety.
▸ A French observational study with TVR- or
BOC-based triple therapy in patients with
cirrhosis reported high frequency of anaemia
and severe adverse events (AEs) particularly in
patients with low platelet counts and low
serum values of albumin (beyond the selection
criteria of registration trials).
What are the new ﬁndings?
▸ We gained further insights into the safety and
efﬁcacy of TVR+PR treatment in 1587 patients
with advanced liver ﬁbrosis or cirrhosis due to
HCV-1 who were enrolled in an open label
expanded access programme to TVR-based
regimen and were selected following
registration trials criteria for platelets,
neutrophils and albumin levels.
▸ During 16 weeks of treatment (12 weeks of
triple therapy followed by 4 weeks of PR)
anaemia was the main side effect as 59% of
patients developed grade 1–4 anaemia (grade
3/4 in 31%), 630 (40%) dose reduced RBV, 332
(21%) received erythropoietin and 157 (10%)
were transfused.
▸ Treatment was safe as 12% of patients had to
discontinue TVR due to AEs and only seven
died (0.4%, six with cirrhosis).
▸ At the end of triple therapy serum HCV RNA
was undetectable in the vast majority of
previous untreated patients and importantly in
72% of 436 patients who had had a prior null
response to PR. The latter is the most difﬁcult
to cure population that was under-represented
in a previous ﬁeld practice study in France.
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related mortality,6–8 factors that may limit both the access as
well as the response rates of patients to triple therapy have been
identiﬁed. Perhaps the most relevant is the presence of advanced
hepatic ﬁbrosis,9–11 which affects tolerability and safety of triple
therapy. The impact of this factor on treatment access and
response rates is driven by an increased rate of
myelosuppression-related adverse events (AEs) such as anaemia
and infections in patients treated with triple therapy.10–13 In
addition, suboptimal dosing due to poor treatment tolerability
may impact the outcome of PI+PR therapy in patients with
advanced ﬁbrosis, leading to reduced rates of virus eradication
and also to unaffordable cost to utility ratios.14 A French obser-
vational study with TVR- and BOC-based triple therapy in
patients with cirrhosis revealed that 33%–46% of the patients
had been ineligible for registration studies with one of these PIs
due to their severe level of liver disease. Up to 11.7% of
patients had to discontinue therapy until week 16 due to the
onset of AEs including anaemia, neutropenia, rash, clinical
decompensation and bacterial infections. In addition, more than
half of the patients on TVR required treatment with bone
marrow stimulating factors and 16.1% received blood transfu-
sions to manage treatment-related anaemia.15 Another real-
world study in Germany showed a high frequency of anaemia
and SAEs in patients with cirrhosis who were treated with triple
therapy, particularly in patients with low platelet counts.16
Therefore, the safety of triple therapy is now being perceived by
hepatologists as a potential barrier to its use in patients with the
most need, such as those with advanced ﬁbrosis, who are more
often vulnerable to myelosuppression-related complications.
To gain further insights into the safety and efﬁcacy of TVR
+PR treatment in patients with advanced liver ﬁbrosis or cirrho-
sis due to HCV-1 infection, an open label expanded access pro-
gramme (EAP) was launched in late 2011 involving 16 nations
worldwide. Cumulatively, the programme enrolled more than
2000 treatment naive or experienced patients with bridging
ﬁbrosis or cirrhosis. We report here the analysis of the
on-treatment virological response and safety in the ﬁrst 1587
patients who reached week 16 of therapy.
PATIENTS AND METHODS
Patients
From August 2011 to March 2013, compensated (Child–Pugh
A) patients with bridging ﬁbrosis or cirrhosis due to HCV-1
infection were enrolled in the TVR EAP at study centres located
in 16 countries across Europe, South America and Australasia.
Key inclusion criteria were male and female gender; ages 18–
70; infection with HCV-1; quantiﬁable serum HCV RNA; and
documentation of liver ﬁbrosis assessed by liver biopsy or a non-
invasive test like Fibrotest or Fibroscan showing severe ﬁbrosis
(Metavir F3 or Ishak 3–4 (S3,4)) or cirrhosis (Metavir F4 or
Ishak 5–6 (S5,6)). Eligible patients had to have an absolute neu-
trophil count >1500/mm3, a platelet count >90 000/mm3 and
haemoglobin (Hb) >12 g/dL for women and 13 g/dL for men.
Patients were excluded if they had history or other evidence of
decompensated liver disease, hepatocellular carcinoma, or if
they were infected or co-infected with HCV other than geno-
type 1, HBV, or HIV or had a history of alcohol abuse.
Additionally, patients were excluded if they had a history of
receiving HCV protease or polymerase inhibitors. The enrol-
ment criteria for the TVR EAP were similar to the REALIZE
study.12
The protocol was signed by the principal site investigators
and approved by the independent ethics committee at each par-
ticipating study centre. All patients provided written informed
consent prior to the conduct of any procedures for the EAP.
Treatment
During the ﬁrst 12 weeks of the programme, all patients
received oral administration of TVR at a dose of 750 mg every
8 h in combination with PR. The type (α 2a vs α 2b PEG-IFN;
copegus vs rebetol) and doses of PR were selected according to
local guidelines. After week 12, PR was administered for
another 12 or 36 weeks depending on the virological response
to treatment and/or previous response type. The concomitant
administration of PR followed label recommendations.17 In
patients with bridging ﬁbrosis who were treatment naive or
prior treatment relapsers, PR was administered for another 12
or 36 weeks based on virological response to treatment as mea-
sured by week 4 and 12 plasma HCV RNA levels. Patients with
undetectable HCV RNA at weeks 4 and 12 received an add-
itional 12 weeks of PR alone (total treatment duration of
24 weeks); patients with detectable HCV RNA (but not meeting
stopping rules) at either week 4 or 12 received an additional
36 weeks of PR alone (total treatment duration of 48 weeks).
Patients with bridging ﬁbrosis with prior partial or null response
to previous treatment with PR including a viral breakthrough
and all patients with cirrhosis were treated for a subsequent
36 weeks. At weeks 4 and 12, patients were assessed as to
whether they met the predeﬁned stopping rules based on viro-
logical response. If at either time point the HCV RNA levels
were greater than 1000 IU/mL, all treatment was permanently
discontinued.
Measures of disease severity and treatment efﬁcacy
Liver ﬁbrosis was staged on histological specimens obtained by
percutaneous liver biopsy using either the Metavir or Ishak
score or by Fibrotest or Fibroscan. Fibroscan cut-off to diagnose
bridging ﬁbrosis and cirrhosis was ≥9.5 kPa and ≥12.5 kPa,
respectively.18 The Child–Pugh score system was used to deﬁne
the clinical status of patients, Child–Pugh A stage indicating
compensated liver disease.
A range of assays were used to measure HCV RNA levels at
local investigational sites. The majority of sites used the Roche
COBAS TaqMan or Abbott RealTime assays (96%). Roche
COBAS TaqMan (versions 1 and 2) has a lower limit of quantiﬁ-
cation (LLOQ) of 15–25 IU/mL depending on serum volume
and the method of RNA extraction with a lower limit of detec-
tion (LLOD) of 10 IU/mL. Abbott RealTime has an LLOQ of
12 IU/mL and an LLOD of 10–12 IU/mL.
In the intent to treat analysis, the number of patients who
had HCV RNA levels below LLOD was calculated for the
overall population (n=1587) and in subgroups by prior treat-
ment history.
Signiﬁcance of this study
How might it impact on clinical practice in the
foreseeable future?
▸ In compensated patients with advanced liver ﬁbrosis due to
HCV-1 who fulﬁlled the selection criteria of registration
trials, 16 weeks of TVR triple therapy proved to be safe,
tolerated and effective.
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Safety assessments
Throughout the treatment period and follow-up, safety assess-
ments were carried out including laboratory assessments, phys-
ical examinations, evaluation of vital signs and the reporting of
AEs. Any clinically signiﬁcant abnormalities persisting at the end
of the EAP/early withdrawal were followed by the investigator
until a resolution or clinical stable endpoint was reached.
The DAIDS criteria were used to grade AEs19 except for rash
which had protocol-speciﬁc deﬁnitions of severity grades: grade
1 mild, localised to one or several isolated sites; grade 2 moder-
ate, diffuse skin eruption involving up to 50% of the body
surface area; grade 3 severe, involving more than 50% of the
body surface area or with signiﬁcant systemic signs or symp-
toms; and grade 4 life-threatening, diagnosis of generalised
bullous eruption, Steven Johnson syndrome or TEN. For
patients who experienced grade 1 or 2 rash, medical manage-
ment was left to the discretion of the investigator. For patients
whose grade 2 rash progressed to grade 3, and for those experi-
encing grade 3 rash, TVR was permanently discontinued. If the
rash did not improve, symptomatically or objectively within
7 days following TVR discontinuation, R was also discontinued.
Immediate and permanent discontinuation of all study drugs
was mandatory for all patients diagnosed with grade 4 rash.
Hb levels were assessed before treatment and at weeks 2, 4, 8
and 12, and as clinically appropriate thereafter; additional visits
could be performed at the discretion of the investigator.
Anaemia was deﬁned as an AE by the investigator in the case
report form, according to the following guidelines: grade 1 Hb
values between 10.0 and 10.9 g/dL or any decrease from base-
line between 2.5 and 3.4 g/dL; grade 2 Hb values between 9.0
and 9.9 g/dL or any decrease of Hb between 3.5 and 4.4 g/dL;
grade 3 Hb values between 7.0 and 8.9 g/dL or any decrease of
Hb ≥4.5 g/dL; and grade 4 an Hb value less than 7.0 g/dL. If
anaemia developed during treatment, R dose was modiﬁed
according to label recommendations. TVR was discontinued
only if reductions of R dose or discontinuation did not result in
an improvement of anaemia. TVR dose reductions were prohib-
ited and TVR could not be reinitiated if treatment was discon-
tinued. Use of blood transfusions, erythropoietin (EPO) or
iron-based products were allowed during the trial.
Statistical methods
Fisher’s exact tests were used to detect differences in the preva-
lence of AEs between patients who were F3 versus F4 at base-
line. Multivariate linear regression was used to identify baseline
factors associated with a higher probability of extended rapid
virological response (eRVR) (deﬁned as HCV RNA undetectable
at both weeks 4 and 12) and development of anaemia (deﬁned
as Hb below 10 g/dL at any time on treatment).
RESULTS
Baseline characteristics
Patient demographics and disease severity are shown in table
1A,B. A total of 746 patients (47%) had bridging ﬁbrosis and
835 patients (53%) a cirrhosis (F4 or S5,6).
Disease stage was assessed by Fibroscan in 1149 patients
(72%), biopsy in 308 patients (19%) and ﬁbrosis markers in
130 patients (8%). Fibrosis stage was classiﬁed by Metavir in
1412 patients (89%) and Ishak in 175 patients (11%). The
mean and SD of the baseline score of Fibroscan was 11.6 kPa
(2.8) for patients classiﬁed as F3 at baseline, and 25.0 kPa
(12.6) for patients classiﬁed as F4 at baseline.
Overall, the mean age of the patients was 53; 1012 patients
(64%) were male and 1557 (98%) were white. In all, 357
patients (22%) were infected with HCV-1a and 1055 (66%)
had HCV RNA greater than or equal to 800 000 IU/mL. At
baseline, 374 patients (24%) had grade 1–3 thrombocytopenia
(platelets <125 000/mm3), while 134 patients (8%) had a grade
2–4 thrombocytopenia (platelets <100 000/mm3). A total of 23
patients (1%) had grade 1–3 reductions in serum albumin
(<3.5 g/dL).
Among the 532 out of 835 cirrhotic patients with currently
available information, 78 patients (14.7%) had either grade or
presence of oesophageal varices reported.
Overall, 321 patients (20%) were treatment naive, 531 (33%)
were prior treatment relapsers, 203 (13%) were prior partial
responders, 436 (27%) were prior null responders and 49 (3%)
had had a viral breakthrough. In all, 47 patients (3%) had had
an unspeciﬁed previous non-response. The demographic and
clinical characteristics were similar between the bridging ﬁbrosis
and cirrhosis study groups.
Efﬁcacy
Overall, 82% of patients at week 4 had a serum HCV RNA
level less than 25 IU/mL, a rate that increased to 86% at week
12. Furthermore, 60% and 82% of patients had undetectable
HCV RNA at weeks 4 and 12, respectively. The percentage of
treatment naive patients who had undetectable HCV RNA
levels at week 12 was 85% whereas among treatment experi-
enced patients, 88% of treatment relapsers, 80% of partial
responders, 72% of null responders and 84% of viral break-
through patients had undetectable HCV RNA levels at week 12.
Figure 1 shows the outcome of treatment at weeks 4 and 12
for each subgroup of patients with respect to previous PR treat-
ment. At week 12, null responders had a signiﬁcantly higher
rate of virological failure (14%) than the other groups (treat-
ment naives (4%), prior relapsers (2%) and partial responders
(5%)). In all, 37 patients (2%) stopped TVR at week 4 having
met the futility rules criteria. Three patients (0.2%) continued
triple therapy despite having met the week 4 virological criteria
for anticipated TVR interruption. The number of patients dis-
continuing triple therapy for AEs was similar in all groups (7%
for treatment naive, 4% for prior relapsers, 7% for partial
responders and 7% for null responders).
In multivariate analysis, four baseline factors were associated
with a higher chance of eRVR: baseline viral load <800 000 IU/
mL (OR=1.47, 95% CI 1.18 to 1.85), genotype 1b (OR=1.52,
95% CI 1.16 to 1.96), α-fetoprotein <10 pg/mL (OR=2.36,
95% CI 1.82 to 3.23) and naive, relapser or prior partial
response versus prior null response (OR=2.0, 95% CI 1.56 to
2.5). The rates of eRVR were 20/50 (40%), 77/235 (33%), 262/
500 (52%), 349/584 (60%) and 173/200 (79%) for patients
with 0, 1, 2, 3 or 4 of these predictive factors, respectively.
There was no association between eRVR and the type of
PEG-IFN used.
Safety and tolerability
Through week 16, 1014 (64%) patients experienced grade 2–4
AEs that were considered related to TVR treatment. The most
common AEs were anaemia (n=698, 44%), rash (n=201,
13%), thrombocytopenia (n=120, 8%), pruritus (n=95, 6%)
and asthenia (n=91, 6%). Patients with cirrhosis developed
more AEs than those with bridging ﬁbrosis (67% vs 60%,
p=0.01). Overall, 12% of patients experienced AEs that ultim-
ately led to TVR discontinuation (table 2). Of the 1587 patients,
seven patients died during the PR tail as a consequence of
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hepatic failure, pneumonia, haemorrhage, septic shock or
ischaemic colitis leading to subsequent multi-organ failure.
Detailed results are shown in table 3.
By week 16, 931 patients (59%) developed any grade
anaemia (table 4). Among patients with bridging ﬁbrosis and cir-
rhosis, 55% and 62%, respectively, had any grade anaemia, with
25% and 29% of the patients developing grade 3 anaemia and
3% and 4% developing grade 4 anaemia, respectively. As
expected, grade 2–4 anaemia judged to be related to TVR treat-
ment occurred more frequently in patients with cirrhosis than in
those with bridging ﬁbrosis (41% vs 47%, p<0.01, table 2). For
treatment of anaemia, 630 patients (40%) underwent R dose
reduction, 332 (21%) received EPO and 157 (10%) received a
blood transfusion. There was combined use of EPO and blood
transfusion in 74 patients (5%), EPO and R dose reduction in
234 patients (15%) and combined use of transfusion and R dose
reduction in 141 patients (9%).
Figure 2 shows the incidence and prevalence rate of any
grade TVR-related anaemia over the 16-week period of study.
In all, 68% of cases of anaemia occurred within the ﬁrst
8 weeks of treatment, and 83% of patients who developed
anaemia throughout treatment were still considered anaemic at
week 16. Table 4 shows the different levels of anaemia recorded
during the ﬁrst 16 weeks of treatment, by baseline ﬁbrosis stage.
Overall, 45 patients (3%; 31 cirrhosis and 14 bridging ﬁbrosis)
discontinued TVR for anaemia, while 27 patients (2%) discon-
tinued R for anaemia.
There were reductions in Hb below 10 g/dL in 48% of
patients. In a multivariate analysis, the four strongest predictors
of Hb <10 g/dL at any time on treatment were female sex
Table 1 Baseline characteristics of the study patients according to disease severity*
Characteristic Bridging fibrosis (N=752)† Cirrhosis (N=835) Overall (N=1587)
Panel A
Age year—mean (range) 52 (22–73) 54 (19–75) 53 (19–75)
Body mass index (BMI)‡ 26±3.7 27±4.2 27±4.0
BMI—range 18–42 19–47 18–47
Males sex—no. (%) 463 (62) 549 (66) 1012 (64)
Race or ethnic group—no. (%)§
White 740 (98) 817 (98) 1557 (98)
Black, Asian or other 12 (2) 18 (2) 30 (2)
HCV-1 subtype—no. (%)
1a 168 (22) 189 (23) 357 (22)
1b 562 (75) 609 (73) 1171 (74)
Missing or unknown 22 (3) 37 (4) 59 (4)
HCV RNA log10—IU/mL, mean (SD)¶ 6.2±0.66 6.1±0.74 6.1±0.71
HCV RNA ≥ 800 000 IU/mL—no. (%) 507 (67) 548 (66) 1055 (66)
Model for End Stage Liver Disease score 7 (6–8) 7 (7–8) 7 (6–8)
α-Fetoprotein—mg/L 5.6 (3.5–10.0) 9.0 (5.3–16.9) 7.1 (4.2–13.1)
Albumin—g/L 44.0 (41.1–46.1) 42.2 (40.0–45.0) 43.0 (40.4–46.0)
Bilirubin—mmol/L 11.8 (8.2–15.4) 13.5 (10.0–17.5) 12.3 (9.0–16.7)
Creatine—mmol/L 69.8 (59.2–79.6) 69.0 (60.0–79.0) 69.0 (59.2–79.6)
Glucose—mmol/L 5.2 (4.7–5.8) 5.4 (4.8–6.3) 5.3 (4.8–6.0)
Haemoglobin—g/L 151 (141–160) 149 (140–159) 150 (140–159)
Neutrophils –×109/L 3.2 (2.5–4.0) 3.0 (2.3–3.8) 3.0 (2.4–3.9)
Platelets –×109/L 182 (149–226) 144 (114–184) 161 (126–205)
Prothrombin intl. normalised ratio 1.0 (1.0–1.1) 1.1 (1.0–1.1) 1.04 (1.00–1.11)
Panel B**
IFNλ-3—no. (%)
Missing or unknown 577 (77) 620 (74) 1197 (75)
CC 23 (3) 50 (6) 73 (5)
CT 117 (16) 121 (14) 238 (15)
TT 35 (5) 44 (5) 79 (5)
Previous type of response—no. (%)
Prior null responder 180 (24) 256 (31) 436 (27)
Prior partial responder 91 (12) 112 (13) 203 (13)
Total non-responders†† 291 (39) 394 (47) 685 (43)
Relapsers 265 (35) 266 (32) 531 (33)
Treatment naive 169 (22) 152 (18) 321 (20)
Viral breakthrough 26 (3) 23 (3) 49 (3)
Unknown 1 (0) 0 (0) 1 (0)
*Values are medians and IQR unless otherwise indicated. Percentages may not total 100 because of rounding.
†Includes three F1 patients and three F2 patients.
‡BMI is the weight in kilograms divided by the square of the height in metres.
§Race or ethnic group was self-reported. Patients of any race could also identify themselves as Hispanic.
¶Log10 values for HCV RNA are means±SE.
**Values are means±SD unless otherwise indicated. Percentages may not total 100 because of rounding.
††Includes prior null responders, prior partial responders and non-responders-unspecified.
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(OR=1.69, 95% CI 1.27 to 2.27, p=0.0004), age>65 years
(OR=2.31, 95% CI 1.46 to 3.65, p=0.0003), low baseline Hb
(OR=1.08, 95% CI 1.06 to 1.09, p<0.0001) and higher
weight-based dosing of R (OR=1.13, 95% CI 1.05 to 1.21,
p=0.0005). Baseline Fibroscan test results were not a signiﬁcant
predictor of anaemia. There was no association between
anaemia and the type of PEG-IFN.
By week 16, 201 patients (13%) had developed a grade 2–4
cutaneous rash that was considered drug-related; these ﬁgures
were similar between patients with bridging ﬁbrosis and those
with cirrhosis (90; 12% vs 111; 13%). Of these, 64 (4%) were
grade 3/4, and 28 cases (2%) were considered serious AEs
including one patient who developed Stevens–Johnson syn-
drome, which resolved after stopping treatment. Overall, 72
patients (5%) discontinued drug treatment for rash of whom 36
had bridging ﬁbrosis and 36 had cirrhosis at baseline (table 2).
Figure 2 shows the incidence and prevalence of any grade
TVR-related rash which, like anaemia, occurred more frequently
during the ﬁrst 8 weeks of therapy (73% of cases). Of patients
who developed rash throughout treatment, 47% of cases were
not resolved by week 16.
While the incidence of grade 2–4 infections considered
treatment-related was low (n=14, 1%), 26 patients (2%) devel-
oped an infection as a serious AE, including seven cases of
pneumonia, two cases of erysipelas, and one case each of sepsis
and septic shock. Only four patients (<1%) discontinued TVR
for infection.
DISCUSSION
The week 16 interim analysis of this EAP provided meaningful
insights on the safety proﬁle and on treatment efﬁcacy of triple
therapy with TVR in patients with histologically advanced hepa-
titis C, a category of patients who are more likely to suffer
treatment-related AEs and to respond less satisfactorily to
IFN-based regimens. Indeed, 12% of the 1587 patients with
either bridging ﬁbrosis or cirrhosis had to prematurely discon-
tinue treatment owing to the onset of AEs, whereas grade 2–4
treatment-related anaemia or a cutaneous rash occurred in 44%
and 13% of the patients, respectively, in the face of 82% of the
overall cohort achieving on treatment clearance of serum
HCV-RNA. Cirrhotic patients experienced slightly more grade
2–4 AEs than did patients with bridging ﬁbrosis.
Table 2 Reasons for discontinuation of telaprevir and the
incidence of the most common grade 2–4 drug-related AEs and
serious AEs
Variable
Bridging
fibrosis (F3)*
(N=752)
Cirrhosis
(F4)
(N=835)
Overall
(N=1587) p Value
Grade 2–4 drug-related AE†—no. (%)
Patients with one or
more AE
453 (60) 561 (67) 1014 (64) <0.01
Anaemia‡ 307 (41) 391 (47) 698 (44) 0.02
Rash‡ 90 (12) 111 (13) 201 (13) NS
Thrombocytopenia‡ 37 (5) 83 (10) 120 (8) <0.01
Pruritus‡ 37 (5) 58 (7) 95 (6) NS
Asthenia 44 (6) 47 (6) 91 (6) NS
Nausea 24 (3) 36 (4) 60 (4) NS
Anorectal‡ 26 (3) 35 (4) 61 (4) NS
Serious AEs§—no. (%)
Patients with one or
more serious AEs
76 (10) 110 (13) 186 (12) NS
Anaemia‡ 32 (4) 43 (5) 75 (5) NS
Rash‡ 12 (2) 16 (2) 28 (2) NS
Infection 6 (1) 20 (2) 26 (2) NS
Pyrexia 4 (1) 8 (1) 12 (1) NS
Reason for discontinuation¶—no. (%)
Any AE 80 (11) 113 (14) 193 (12) NS
Rash‡ 36 (5) 36 (4) 72 (5) NS
Anaemia‡ 14 (2) 31 (4) 45 (3) 0.01
Vomiting 8 (1) 9 (1) 17 (1) NS
Asthenia 6 (1) 10 (1) 16 (1) NS
Nausea 7 (1) 9 (1) 16 (1) NS
Pruritus‡ 3 (0) 10 (1) 13 (1) NS
Abdominal pain 1 (0) 8 (1) 9 (1) NS
*Includes three F1 patients and three F2 patients.
†Listed are grade 2–4 drug-related AEs that occurred in at least 4% of the overall
population.
‡Included in this category are all related events that were described with a variety of
descriptive terms.
§Listed are serious AEs that occurred in at least 0.5% of the overall population.
¶Listed are discontinuations that occurred in at least 1% of the overall population.
These figures are the number of patients who discontinued telaprevir; patients may
have continued treatment with pegylated interferon plus ribavirin.
AE, adverse event.
Figure 1 Outcome of treatment at
weeks 4 and 12, by prior treatment.
Shown are the week 4 and 12
outcomes of treatment by subgroup:
treatment naive (n=321), prior
treatment relapsers (n=531), previous
partial responders (n=436) and
previous null (n=203). Data for
patients who had previously
experienced viral breakthrough (n=49)
and whose prior response to treatment
was unspeciﬁed (n=47) have not been
represented.
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Owing to the multifactorial origin of anaemia in patients with
advanced liver ﬁbrosis including age, myelosuppression and
impaired renal function, higher rates of grade 3 or 4 anaemia
were observed in EAP patients than those observed in phase II/
III studies (31% in the EAP compared with 4%–18% previously
reported).11 12 15 20 21 These discrepancies can be accounted for
by the fewer number of patients enrolled in clinical develop-
ment studies who had either bridging ﬁbrosis or cirrhosis (ie, an
advanced liver disease entailing a signiﬁcant risk of developing
myelosuppression-related AEs). Additionally, our choice of
deﬁning anaemia as either Hb below given threshold levels or
any decrease of Hb following triple therapy could have
increased the estimate of anaemia in some patients. In all, 40%
of the overall cohort had anaemia managed with R dose reduc-
tion and blood transfusion was used in 10%. In contrast to the
registration trial protocols where the use of EPO to correct
anaemia was not permitted,11 12 332 patients (21%) received
EPO. In addition, a signiﬁcant proportion of patients had their
anaemia treated through a combination of R dose reduction/
interruption and either EPO or blood transfusion. It is possible
that R dose reduction to manage anaemia was avoided because
of concerns that treatment effectiveness may be compromised;
however, it is now appreciated from both a retrospective and
prospective study with TVR and BOC, respectively, that R dose
reduction may not affect sustained virological response (SVR)
rates.22 23 Overall, the strategies of anaemia management in this
study resulted in only 3% of patients discontinuing TVR
because of anaemia. This compares with 2% of patients in the
REALIZE study who discontinued TVR for anaemia.12
Similar rates of anaemia were reported in patients with com-
pensated cirrhosis who were enrolled in the ﬁeld practice study
CUPIC in France, where 29% had grade 3 anaemia (deﬁned as
Hb <9 g/dL);15 this was despite a higher number of CUPIC
patients (33%) with severe liver impairment exceeding the
enrolment criteria adopted in REALIZE than in the EAP
(9%).12 The clinical burden of anaemia in CUPIC was higher
than in the EAP, with EPO use in more than half of the patients
(57%) or the need for blood transfusion in 15% possibly reﬂect-
ing slightly more advanced liver disease in CUPIC patients.
Not unexpectedly, anaemia deﬁned as a Hb drop below 10 g/dL
following PR+TVR therapy more often occurred in
>65-year-old patients, women and patients with low pretreat-
ment Hb values or those with higher weight-based dosing of
R. While age is a well-recognised risk factor for anaemia in
patients with advanced liver disease, likely reﬂecting an
increased susceptibility to treatment-related bone marrow and
renal toxicity, female gender and low pretreatment Hb values
Table 3 Adverse events with fatal outcome (n=1587)
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7
Age 52 51 50 55 60 66 56
Gender Male Female Female Male Male Male Male
Fibrosis
stage
F4 F4 F4 F3 F4 F4 F4
BSL VL 1 200 000 2 387 203 389 340 3 180 000 1 430 000 977 100 2 502 935
Last obs.
VL
Undetectable Undetectable 20 570 Undetectable – –
Dates of
TVR
treatment
July 2011 to September 2011 December 2011
to February 2012
January 2012 to
April 2012
September 2011 to
December 2011
November 2011
to February 2012
May 2012 to July
2012
April 2012 to
July 2012
Date of
death
4 weeks after TVR d/c 2 weeks after
TVR d/c
4 weeks after TVR
d/c
30 weeks after TVR d/c 4 weeks after
TVR d/c
24 weeks after
TVR d/c
8 weeks after
TVR d/c
Adverse
event
Anaemia, dehydration, hepatic
failure, hepatorenal syndrome,
hyper-catabolism,
keto-acidosis, multi-organ
failure
Ischaemic colitis,
septic shock,
multi-organ
failure
Hepatic failure,
bone marrow
failure,
multi-organ
failure
Anaemia, hepatic
neoplasm malignant,
intra-abdominal
haemorrhage,
pneumonia
Anaemia,
oesophageal
variceal
haemorrhage
Diarrhoea, vomit,
hypotension,
septic shock,
coma
Anaemia,
fatigue,
pneumonia
Causality Possibly related Related Unlikely related Unlikely/not related Unlikely related Not related Unlikely
related
Medical
history
Diabetes Low platelets
(74 000)
Neutropenia
(830 cells/mm3)
BSL, baseline; d/c, discontinued; TVR, telaprevir; VR, viral load.
Table 4 Week 16: Prevalence and management of anaemia by
fibrosis stage
Characteristic
Bridging
fibrosis (F3)*
(N=752)
Cirrhosis
(F4) (N=835)
Overall
(N=1587)
Grade 1–4 anaemia† (all
cause)—no. (%)
413 (55) 518 (62) 931 (59)
Grade 3 anaemia† (all cause)—
no. (%)
189 (25) 238 (29) 427 (27)
Grade 4 anaemia† (all cause)—
no. (%)
26 (3) 35 (4) 61 (4)
d/c TVR due to anaemia†—
no. (%)
14 (2) 31 (4) 45 (3)
Initial RBV dose (mg/day)—
mean
1106 1120 1114
Initial RBV dose (mg/kg/day)—
mean
14.6 14.3 14.4
RBV dose reductions—no. (%) 270 (36) 356 (43) 630 (40)
EPO use—no. (%) 138 (19) 194 (23) 332 (21)
Blood transfusion—no. (%) 60 (8) 96 (12) 157 (10)
RBV dose reduction+other
intervention (EPO or blood
transfusion)—no. (%)
126 (17) 182 (22) 309 (20)
*Includes three F1 patients and three F2 patients.
†Included in this category are all related events that were described with a variety of
descriptive terms.
d/c, discontinued; EPO, erythropoietin; RBV, ribavirin; TVR, telaprevir.
Colombo M, et al. Gut 2014;63:1150–1158. doi:10.1136/gutjnl-2013-305667 1155
Hepatology
have long been recognised as risk factors for anaemia also in
patients exposed to dual therapy with PR.24 25
One reassuring ﬁnding of the TVR EAP was the low rate of
cutaneous rash (13% grade 2–4 treatment-related), and in par-
ticular of grade 3–4 rash affecting 4% of the population only.
This may reﬂect the improved standard of care based on inter-
ventions and counselling to prevent cutaneous toxicity of TVR.
This is not unprecedented since the rates of any grade rash were
already reduced in phase III registration trials compared with
the phase II trials where rash was a leading AE causing a shor-
tened period of TVR administration.15 26 Similarly, rather low
rates (4.8%) of grade 3/4 rash were also observed in the CUPIC
study.15
In the EAP, a number of patients developed AEs other than
anaemia or rash, including infections, thrombocytopenia, prur-
itus, weakness, nausea and anorectal discomfort. Similar to the
cutaneous rash, anorectal discomfort was reported for a lower
proportion of patients than in registration trials,11 12 20 21 26
again possibly reﬂecting improved standard of care based on the
use of prophylactic and therapeutic remedies. Ultimately, only
12% of patients experienced SAEs including anaemia (5%), rash
(2%), infection (2%) and pyrexia (1%). Thus, enrolment of
patients fulﬁlling the selection criteria to the registration trials
and well compensated liver status resulted in a satisfactory safety
record of TVR-based regimens in patients with advanced liver
ﬁbrosis. This explains also the low mortality rates (n=7, 0.4%)
in the EAP cohort up to week 16. Deaths were the consequence
of multi-organ failure caused by infection in two patients, pneu-
monia in two patients, and septic shock, ischaemic colitis, and
haemorrhage in one patient each. Notably, one of these patients
suffered from diabetes, a disease known to increase the risk of
infection, and six of the seven patients had cirrhosis. PR-related
deaths were reported also in patients with cirrhosis due to HCV
(2%) who were enrolled in a trial aiming to evaluate the safety
and efﬁcacy of elthrombopag,27 a synthetic compound able to
increase the level of circulating platelets. Slightly higher rates
(2.8%) of TVR treatment-related deaths were reported in
patients with cirrhosis who were enrolled in the CUPIC study15
where mortality was almost invariably associated with liver
failure and predicted by signs of impaired liver function includ-
ing a baseline platelet count less than 100 000/mm3 and serum
albumin lower than 3.5 g/dL. In this study, TVR-based regimens
were also associated with a signiﬁcant rate of infection (6.5%).
With respect to the TVR EAP, the greater burden of AEs and
serious complications (29 among 429 patients) observed in the
CUPIC study during the ﬁrst 16 weeks of triple therapy under-
score the enrolment of a signiﬁcant number of patients with
deteriorated liver function. In the French study, 20% of patients
Figure 2 Incidence and prevalence
of any grade telaprevir (TVR)-related
anaemia (A) and rash (B). Shown are
the incidence and prevalence rates of
the Intent to Treat population by
month from start of TVR treatment.
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had <100 000 platelets and 12% <3.5 g albumin compared
with TVR EAP where these ﬁgures were 8% and 1%, respect-
ively. Poor safety signals in patients with more profound liver
derangement were reported in two studies in Germany16 and
Austria28 where the prevalence of patients with severe liver
impairment was intermediate between CUPIC and TVR EAP.
The ﬁnding that 85% of previously untreated patients had
undetectable HCV RNA at week 12 with minor differences
between patients with bridging ﬁbrosis and those with cirrhosis
(87% vs 83%) is similar to the antiviral efﬁcacy of TVR regimens
seen in registration trials. Based on previous phase III trial
results, one may therefore predict that a signiﬁcant proportion of
previously untreated patients with advanced ﬁbrosis will ultim-
ately achieve an SVR upon completion of the treatment sched-
ule.11 21 Still, the SVR results need to be conﬁrmed in long-term
follow-up. In most countries, treatment naive patients with
advanced ﬁbrosis have been prioritised to receive triple therapy
with TVR. The EAP study also provides encouraging though pre-
liminary data of the efﬁcacy of TVR triple therapy in treatment
experienced patients with bridging ﬁbrosis and cirrhosis. These
ﬁndings were particularly rewarding for those individuals with a
previous relapse or partial response to PR, reaching very high
HCV RNA undetectability rates of 88% and 80% at week 12. A
preliminary report of the CUPIC study is in line with our obser-
vation and predictions of SVR in experienced patients with
advanced ﬁbrosis/cirrhosis, with 46% of 107 patients enrolled in
the study achieving an SVR at week 12 post-treatment.22 One
important limit of the CUPIC study, however, is the under-
representation of null responders, who are most difﬁcult to cure,
as a consequence of their poor IFN sensitivity, leading to a high
risk of virological breakthroughs and post-treatment relapse of
hepatitis. By enrolling 436 patients who had had a prior null
response (180 bridging ﬁbrotic and 256 cirrhotic patients), the
EAP is the largest study of prior null responders.
In conclusion, the 16-week interim analysis of the TVR EAP in
1587 patients provided encouraging insights on the safety, toler-
ability and preliminary efﬁcacy of TVR triple therapy in difﬁcult
to cure categories of hepatitis C patients with advanced ﬁbrosis.
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